Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), a precision cardiovascular medicine company driven by artificial intelligence (AI), announced on Wednesday that it has appointed Dr Vimal Ramjee, MD FACC CCMS, as a Strategic Advisor.
A distinguished cardiologist and health innovation leader, Dr Ramjee holds key roles including National Co-Chair of Cardiology and Innovation at CommonSpirit Health Enterprise and is a member of the American Heart Association Board of Directors.
This strategic appointment signifies a crucial step in Cardio Diagnostics' growth and market expansion. Dr Ramjee's extensive experience in clinical practice, innovation and research positions him as a valuable asset, aiming to accelerate the company's mission of enhancing patients' lives through advancements in cardiovascular disease prevention, treatment and management. His role will focus on driving opportunities for research, collaborations and partnerships.
Dr Ramjee's illustrious career in cardiovascular medicine spans academic and professional achievements, with expertise at the intersection of medicine, digital health technologies and AI algorithms. His strategic contributions align with Cardio Diagnostics' commitment to pushing the boundaries of precision cardiovascular medicine.
As a Strategic Advisor, Dr Ramjee will collaborate with Cardio Diagnostics' management team on various initiatives, including new research studies and exploring emerging opportunities. Additionally, he will work towards raising awareness of Cardio Diagnostics' innovative technologies, emphasizing its potential to elevate patient care and ensuring the company remains a leader in precision cardiovascular medicine.
Cardio Diagnostics, with its focus on AI-powered precision cardiovascular medicine, aims to make disease prevention, detection, and management more personalised, accessible and precise. The company's proprietary AI-driven Integrated Genetic-Epigenetic Engine positions it as a forefront player in medical technology, dedicated to improving the prevention, detection, and treatment of cardiovascular disease.
AstraZeneca completes acquisition of Amolyt Pharma
CureLab Oncology names new CMO
Tempus announces receipt of FDA clearance for AI-based AFib risk detection
Revelation Biosciences' Phase 1 study shows promising results for TLR4 agonist Gemini
Smartcella adds new board members
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Haemonetics' TEG 6s hemostasis cartridge gains FDA clearance
Polymedco's PATHFAST hs-cTnI-II test receives US FDA clearance
Gilgamesh Pharmaceuticals receives multi-year USD14m grant from NIDA
Advanced Medical Solutions Group plc proposes GBP120.8m acquisition of Peters Surgical
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes